Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 27;25(9):4785.
doi: 10.3390/ijms25094785.

SIRT1 Serum Concentrations in Lipodystrophic Syndromes

Luisa Salvatori  1 , Silvia Magno  2 , Giovanni Ceccarini  2 , Rossella Tozzi  3 , Savina Contini  4 , Caterina Pelosini  5 , Ferruccio Santini  2 , Lucio Gnessi  4 , Stefania Mariani  4
Affiliations

SIRT1 Serum Concentrations in Lipodystrophic Syndromes

Luisa Salvatori et al. Int J Mol Sci. .

Abstract

Lipodystrophies (LDs) are rare, complex disorders of the adipose tissue characterized by selective fat loss, altered adipokine profile and metabolic impairment. Sirtuins (SIRTs) are class III NAD+-dependent histone deacetylases linked to fat metabolism. SIRT1 plays a critical role in metabolic health by deacetylating target proteins in tissue types including liver, muscle, and adipose. Circulating SIRT1 levels have been found to be reduced in obesity and increased in anorexia nervosa and patients experiencing weight loss. We evaluated circulating SIRT1 levels in relation to fat levels in 32 lipodystrophic patients affected by congenital or acquired LDs compared to non-LD subjects (24 with anorexia nervosa, 22 normal weight, and 24 with obesity). SIRT1 serum levels were higher in LDs than normal weight subjects (mean ± SEM 4.18 ± 0.48 vs. 2.59 ± 0.20 ng/mL) and subjects with obesity (1.7 ± 0.39 ng/mL), whereas they were close to those measured in anorexia nervosa (3.44 ± 0.46 ng/mL). Our findings show that within the LD group, there was no relationship between SIRT1 levels and the amount of body fat. The mechanisms responsible for secretion and regulation of SIRT1 in LD deserve further investigation.

Keywords: SIRT1; adipokines; adipose tissue; lipodystrophy.

PubMed Disclaimer

Conflict of interest statement

G.C. has received fees for consulting and/or received travel funds or participated in studies from the following companies, which are involved with lipodystrophy and/or diabetes: Aegerion/Amryt Pharmaceuticals, Novo-Nordisk, and Rhythm Pharmaceuticals. S.M. (Silvia Magno) and C.P. have received travel funds from Amryt Pharmaceuticals, which is involved with lipodystrophy. F.S. has worked as a consultant, participated in studies, and/or received travel funds from the following companies, which are involved with lipodystrophy and/or diabetes: Aegerion/Amryt, Novo Nordisk, Lilly, Bruno Pharma, and Pfizer. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Correlation between fat percentage in the whole body and SIRT1 serum concentrations in patients with different subtypes of LD: generalized lipodystrophy (GL, n = 3), progeroid syndromes (PS, n = 5), familial partial lipodystrophy type 1 (FPLD1, n = 4), familial partial lipodystrophy type 2 (FPLD2, n = 7), and acquired partial lipodystrophy (APL, n = 10). r2 = 0.002489, p = 0.79.
Figure 2
Figure 2
Comparison of SIRT1 serum concentrations in patients with lipodystrophies (LD, n = 32), anorexia nervosa (AN, n = 24), obesity (OB, n = 24) and normal weight subjects (NW, n = 22). Values are expressed as means ± standard error (SEM). * p < 0.05.
See this image and copyright information in PMC

References

    1. Araújo-Vilar D., Santini F. Diagnosis and treatment of lipodystrophy: A step-by-step approach. J. Endocrinol. Invest. 2019;42:61–73. doi: 10.1007/s40618-018-0887-z. - DOI - PMC - PubMed
    1. Garg A. Lipodystrophies. Am. J. Med. 2000;108:143–152. doi: 10.1016/s0002-9343(99)00414-3. - DOI - PubMed
    1. Araújo-Vilar D., Fernández-Pombo A., Cobelo-Gómez S., Castro A.I., Sánchez-Iglesias S. Lipodystrophy-associated progeroid syndromes. Hormones. 2022;21:555–571. doi: 10.1007/s42000-022-00386-7. - DOI - PubMed
    1. Akinci G., Celik M., Akinci B. Complications of lipodystrophy syndromes. Presse. Med. 2021;50:104085. doi: 10.1016/j.lpm.2021.104085. - DOI - PubMed
    1. Pardini V.C., Victória I.M., Rocha S.M., Andrade D.G., Rocha A.M., Pieroni F.B., Milagres G., Purisch S., Velho G. Leptin levels, beta-cell function, and insulin sensitivity in families with congenital and acquired generalized lipoatropic diabetes. J. Clin. Endocrinol. Metab. 1998;83:503–508. doi: 10.1210/jcem.83.2.4567. - DOI - PubMed